UNSPSC 51172324: Mesna

This classification denotes a uroprotective agent with the molecular formula C2H5O3S2.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NR7O1405Q9, chemically known as ethanesulfonic acid, 2-mercapto-, monosodium salt but generally known as mesna, which bears US NIH Compound Identifier 598. European Medicines Agency schedules Mesna in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08784MIG.

UNSPSC 51172324 Mesna, a Commodity code, encompasses pharmaceutical products and testing services procured by state and local health and criminal justice agencies. Recent state and local solicitations under this code reflect two distinct procurement streams: specimen collection and drug testing services for offender supervision programs, and direct-to-manufacturer pharmaceutical supply arrangements for state health benefit programs and correctional facilities. The issuing bodies include county community supervision departments (Collin County Community Supervision and Corrections Department in Texas), state health and human services commissions (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances serving participating state and local government members (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP).

Texas and Minnesota dominate recent activity. Collin County Community Supervision and Corrections Department posted an RFP (2026-327, due July 23, 2026) for offender specimen collection and drug testing services at two sites in the Dallas-Fort Worth region, with an estimated contract value of $600,000 over two years and three optional one-year renewals, requiring SAMHSA, Texas Department of Public Safety, or CAP lab certification and per-test pricing for approximately 25,031 annual tests using immunoassay screening with LC/MS/MS or GC/MS confirmation. The Texas Health and Human Services Commission issued a Request for Information (RFI HHS0017013, posted April 3, 2026) soliciting vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to establish direct relationships between state pharmacy benefit programs and manufacturers. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and over-the-counter products distributed through three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), with contract effectiveness July 1, 2026, and evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 15 percent combined on administrative compliance, EDI capability, and administrative fee agreement.